NOTICIAS

New guidance on processing of applications for regulated products

New guidance on processing of applications for regulated products

An administrative guidance published today sets out the principles that EFSA follows when processing applications for regulated products. This is part of EFSA’s continuous efforts to support applicants throughout the life-cycle of their applications. The guidance...

DATA INTEGRITY REFERENCES

REFERÊNCIAS: .-EMA: Questions and answers: Good manufacturing practice - Data Integrity Section .-FDA: FDA Data Integrity Guidance .-MHRA: MHRA Data Integrity Definitions and Guidance .-PIC/S: PIC/S Guidance .-WHO: WHO Guidance

Data Standards Strategy FY2018-FY2022

The purpose of the CBER-CDER Data Standards Strategy is to reinforce the ongoing commitment to the development, implementation, and maintenance of a comprehensive data standards program that will facilitate the pre- and postmarket regulatory review process so that...

Monitoring, Analyzing and Interpreting Regulatory Trends

Monitoring, Analyzing and Interpreting Regulatory Trends

Posted 24 January 2018 | By João Duarte Regulatory Focus. January 2018. Regulatory Affairs Professionals Society. This article discusses ways in which the regulatory intelligence professional can monitor, identify, analyze, interpret and "stay on top" of regulatory...

TELLING STORIES: HOW LEADERS CAN INFLUENCE, TEACH, AND INSPIRE

TELLING STORIES: HOW LEADERS CAN INFLUENCE, TEACH, AND INSPIRE

Telling Stories: How Leaders Can Influence, Teach, and Inspire Vanessa Boris and Lani Peterson December 2017 • Harvard Business Publishing Part of the work of a leader is to influence—to teach, convince,and inspire those around them. That includes their staffs, their...

Is an orphan medicine still an orphan once it gets on the market?

Is an orphan medicine still an orphan once it gets on the market?

EMA publishes additional reports on decision-making for orphan medicines, an initiative that addresses requests from stakeholders. The new reports summarise the reasoning of the Agency’s Committee for Orphan Medicinal Products (COMP) on whether or not a medicine...

FDA Drafts PRV Guidance for Medical Countermeasures

This guidance provides information on implementation of section 3086 of the 21st Century Cures Act (Cures Act) (Public Law 114-255), which added section 565A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360bbb-4a). Section 565A of the FD&C...

Nova Creditação OF para o curso: Boas Práticas de Fabrico . GMP 2018

Nova Creditação OF para o curso: Boas Práticas de Fabrico . GMP 2018

O curso Boas Práticas de Fabrico GMP 2018 para o próximo dia 30 de janeiro de 2018, conduzido pela reputada formadora Drª Fernanda Ralha, do Infarmed, foi creditado com 0.563 CDP   Nesta formação tem a oportunidade de ver abordados assuntos como : Novos conceitos...

AVALIAÇÃO CLÍNICA de PRODUTOS de SAÚDE  Lisboa, 17 de abril de 2018

AVALIAÇÃO CLÍNICA de PRODUTOS de SAÚDE Lisboa, 17 de abril de 2018

Apresentamos a 2ª edição da formação AVALIAÇÃO CLÍNICA de PRODUTOS de SAÚDE, para o dia  17 de abril de 2018, conduzido pela reputada especialista Dra. Sónia Ferreira,Diretora Técnica.Diretora de Qualidade.Responsável de Farmacovigilância, da A. MARTINS &...

Actualização nas BOAS PRATICAS DE FARMACOVIGILÂNCIA

Actualização nas BOAS PRATICAS DE FARMACOVIGILÂNCIA

Final GVP modules Document(s) Language Status First published Last updated Effective Date Guideline on good pharmacovigilance practices: Module I – Pharmacovigilancesystems and their quality systems (English only) adopted 25/06/2012 02/07/2012 Guideline on good...

PGEU Best Practice Paper: Pharmacovigilance and Risk Minimisation

PGEU Best Practice Paper: Pharmacovigilance and Risk Minimisation

This best practice paper outlines the evolution of pharmacovigilance in Europe, particularly in the context of the fifth anniversary of the 2012 EU pharmacovigilance legislation and recent developments in the field. Additionally, this paper describes the varied role...

Refuse to File: NDA and BLA Submissions to CDER

The purpose of this guidance is to clarify circumstances under which the FDA’s Center for Drug Evaluation and Research (CDER) may refuse to file a new drug application (NDA) or supplemental NDA (21 CFR 314.101(d)) or a biologics license application (BLA) or...

FDA promotes faster digital health regulation

The purpose of this guidance is to identify the types of decision support software functionalities  that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the  definition of a device but for which FDA does not intend to enforce...

FDA Guidance : Pediatric rare diseases

The emergence of concomitant trials for multiple investigational drug products for the treatment of rare diseases can pose significant challenges to effective drug development due to the limited number of patients worldwide with any given rare condition. The purpose...

FDA eCTD TECHNICAL CONFORMANCE GUIDE

Guidance for Industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications DOWNLOAD

Guidance to help pharma companies prepare for Brexit

Guidance to help pharma companies prepare for Brexit

Additional guidance relates to medicines for human and veterinary use The European Medicines Agency (EMA) has published additional guidance to help pharmaceutical companies prepare for the United Kingdom’s (UK) withdrawal from the European Union (EU). The guidance...

FDA Updates Orange Book With Patent Submission Dates

FDA introduces patent submission date updates to the Orange Book On November 21, 2017, the U.S. Food and Drug Administration (FDA) introduced an important data update to Approved Drug Products with Therapeutic Equivalence Evaluations – known as the “Orange Book.”...

New guidelines on good manufacturing practices for advanced therapies

New guidelines on good manufacturing practices for advanced therapies

Adaptations ensure a high level of quality for ATMPs and patient protection The European Commission has published a set of guidelines on good manufacturing practice (GMP) specific to advanced therapy medicinal products (ATMPs). ATMPs are medicines for human use that...

Data Integrity – Implementation status

Data Integrity – Implementation status

Checking the regulations and newsletters available for the pharmaceutical industry, data integrity is still the most prominent topic. Driven by various inspections since 2012/2013 this trend has meanwhile arrived at small and medium sized pharmaceutical companies. As...